JP2021004249A5 - - Google Patents

Download PDF

Info

Publication number
JP2021004249A5
JP2021004249A5 JP2020155978A JP2020155978A JP2021004249A5 JP 2021004249 A5 JP2021004249 A5 JP 2021004249A5 JP 2020155978 A JP2020155978 A JP 2020155978A JP 2020155978 A JP2020155978 A JP 2020155978A JP 2021004249 A5 JP2021004249 A5 JP 2021004249A5
Authority
JP
Japan
Prior art keywords
months
composition
hiv
pro140
infected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020155978A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021004249A (ja
JP7035143B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2021004249A publication Critical patent/JP2021004249A/ja
Publication of JP2021004249A5 publication Critical patent/JP2021004249A5/ja
Application granted granted Critical
Publication of JP7035143B2 publication Critical patent/JP7035143B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020155978A 2014-08-20 2020-09-17 代替処置としてのｈｉｖ抗体療法 Expired - Fee Related JP7035143B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462039620P 2014-08-20 2014-08-20
US62/039,620 2014-08-20
US201562192941P 2015-07-15 2015-07-15
US62/192,941 2015-07-15

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017529600A Division JP6767367B2 (ja) 2014-08-20 2015-08-20 代替処置としてのｈｉｖ抗体療法

Publications (3)

Publication Number Publication Date
JP2021004249A JP2021004249A (ja) 2021-01-14
JP2021004249A5 true JP2021004249A5 (enExample) 2021-02-25
JP7035143B2 JP7035143B2 (ja) 2022-03-14

Family

ID=55351264

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017529600A Expired - Fee Related JP6767367B2 (ja) 2014-08-20 2015-08-20 代替処置としてのｈｉｖ抗体療法
JP2020155978A Expired - Fee Related JP7035143B2 (ja) 2014-08-20 2020-09-17 代替処置としてのｈｉｖ抗体療法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017529600A Expired - Fee Related JP6767367B2 (ja) 2014-08-20 2015-08-20 代替処置としてのｈｉｖ抗体療法

Country Status (11)

Country Link
US (2) US10562969B2 (enExample)
EP (2) EP3904390A1 (enExample)
JP (2) JP6767367B2 (enExample)
KR (1) KR20170042706A (enExample)
CN (1) CN106661113A (enExample)
AU (2) AU2015305401A1 (enExample)
BR (1) BR112017003252A2 (enExample)
CA (1) CA2957817A1 (enExample)
ES (1) ES2880950T3 (enExample)
MX (1) MX2017002093A (enExample)
WO (1) WO2016029049A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016210130A1 (en) 2015-06-23 2016-12-29 Cytodyn Inc. Inhibition of ccl5 ligand binding to ccr5 receptor and alteration of ccr5/ccl5 axis signaling in inflammation, cancer, autoimmune, and other conditions
CA3089848A1 (en) * 2017-09-18 2019-03-21 Cytodyn Inc. Screening methods for identifying and treating hiv-1 infected patient sub-populations suitable for long term anti-ccr5 agent therapy
WO2024008177A1 (en) * 2022-07-08 2024-01-11 Nanjing Curegene Technology Co., Ltd. Engineered cells and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122185B2 (en) * 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
CN1805740A (zh) 2003-05-16 2006-07-19 马里兰大学生物技术研究所 下调ccr5表达的组合物及其应用方法
CN101495145A (zh) * 2005-07-22 2009-07-29 原基因药物有限公司 用于减少受hiv-1感染的患者中病毒负荷的方法
WO2008134076A1 (en) * 2007-04-30 2008-11-06 Progenics Pharmaceuticals, Inc. Methods for reducing viral load in hiv-1-infected patients
US10500274B2 (en) * 2008-04-30 2019-12-10 Cytodyn Inc. Methods for reducing viral load in HIV-1 infected patients
RU2626512C2 (ru) * 2010-03-01 2017-07-28 Цитодин, Инк. Концентрированные белковые фармацевтические составы и их применение

Similar Documents

Publication Publication Date Title
JP7559175B2 (ja) Ｈｉｖおよびエイズの治療および予防方法
JP2023553393A (ja) うつ病患者の自殺リスク低減のためのブプロピオンおよびデキストロメトルファン
JP6353577B2 (ja) 組み合わせ組成物
Kemper et al. Mexiletine for HIV-infected patients with painful peripheral neuropathy: a double-blind, placebo-controlled, crossover treatment trial
JP2021004249A5 (enExample)
JP2022062170A5 (enExample)
JP2018513188A5 (enExample)
IL292706A (en) Type i interferon inhibition in systemic lupus erythematosus
JP2018531605A5 (enExample)
CN102083435A (zh) 特拉匹韦给药方案
Wedemeyer et al. 96 weeks of pegylated-Interferon-alpha-2a plus tenofovir or placebo for the treatment of hepatitis delta: the HIDIT-2 study: 31
EP3393517B1 (en) Acetylsalicylic acid for use in the treatment of moderate to severe influenza
WO2016053121A1 (en) Antiviral pharmaceutical formulation for the treatment of dengue, influenza and hiv/aids
JP2005529152A5 (enExample)
CN112996517A (zh) 预防hiv的整合酶抑制剂
JP2019038858A (ja) ペマフィブラートを含有する医薬
Yakubova et al. Safety and PK study of VM-1500A-LAI, a novel long-acting injectable therapy for HIV
RU2840191C1 (ru) Способ лечения пациентов с вич-инфекцией
Elliott et al. Cabotegravir extended-release and rilpivirine injectable suspension (Cabenuva) and cabotegravir tablets (Vocabria)
WO2014037121A1 (en) Use of rifapentine in the treatment of tuberculosis in patients infected with the human immunodeficiency virus (hiv) / acquired immune deficiency syndrome (aids) and treated with an antiretroviral combination
JP2019508399A (ja) 多くの治療を経験したｈｉｖ−１に感染した個体において使用するためのホステムサビル
Elliott et al. Fostemsavir extended-release tablets (Rukobia)
Rizza et al. Novel HIV drugs and drug delivery strategies. A report from the 2018 Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts, USA-March 4-7, 2018
CN117017986A (zh) 康替唑胺在制备抗结核病药物中的应用
RU2022102380A (ru) Способы лечения инфекции, вызванной вич, у пациентов детского возраста с применением рилпивирина